ArticleRespiratory research & clinical practice2026
Pneumonia in lung transplant recipients: the role of donor, recipient, and hospital-acquired microorganisms.
Article in Respiratory research & clinical practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Donor-derived disease is an inherent risk in solid organ transplantation, especially lung transplantation (LTx), because of direct contact between the organ and the external environment, and the consequences of lung denervation after LTx. We sought to demonstrate the burden of pneumonia after LTx in a large center in Brazil, characterizing the main source of infection and its associated mortality. Methods: We performed a retrospective analysis of all LTx procedures occurring between 2017 and 2023 at a public center in Brazil. All microorganisms isolated from the donor BAL fluid and the recipient bronchial secretions at organ harvest were compared with those found by postoperative day 14 and classified as donor-derived, recipient colonization-related, or hospital-acquired pneumonia. We analyzed the characteristics of donors and recipients, as well as the associated mortality. Results: Donor-derived pneumonia was found in 8/149 patients (5.36%) who received lungs from infected donors. In all cases, donor-derived pneumonia was due to gram-negative bacilli, all of which showed drug resistance, causing a 50% mortality rate. Recipient colonization-related pneumonia occurred in 14/107 patients (13%), being mostly due to Pseudomonas aeruginosa (in 58.8%), with a 28.6% risk of death. Hospital-acquired pneumonia occurred in 17 of 217 recipients (7.83%), being mainly due to Acinetobacter baumannii (in 20%), P. aeruginosa (in 15%), Klebsiella pneumoniae (in 10%), Stenotrophomonas maltophilia (in 10%), or Burkholderia cepacia (in 10%), with a mortality rate of 50%. Conclusions: Although infrequent, donor-derived pneumonia appears to be associated with high early mortality, comparable to that for hospital-acquired pneumonia. Recipient colonization-related and hospital-acquired pneumonia are linked to an increased chance of death, especially in patients colonized with P. aeruginosa and those with extensively drug-resistant bacteria, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.